Related Experiment Video
Updated: Oct 30, 2025
Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
Published on: October 19, 2013
Specialized Pro-Resolving Lipid Mediators in Neonatal Cardiovascular Physiology and Diseases
Andrea Gila-Diaz1, Gloria Herranz Carrillo2, Pratibha Singh3
1Department of Physiology, Faculty of Medicine, Universidad Autónoma de Madrid, C/Arzobispo Morcillo 2, 28029 Madrid, Spain.
Insights
Specialized Pro-Resolving Mediators (SPMs) from long chain polyunsaturated fatty acids (LCPUFAs) can resolve inflammation and aid tissue repair. This review explores their role in neonatal cardiovascular health and disease, offering potential therapeutic insights.
Area of Science:
- Cardiovascular Research
- Inflammation Biology
- Neonatal Medicine
Background:
- Cardiovascular disease is a major global health concern, with unresolved inflammation being a key factor.
- Specialized Pro-Resolving Mediators (SPMs), derived from long chain polyunsaturated fatty acids (LCPUFAs), are crucial for resolving inflammation and promoting tissue repair.
- Existing research on SPMs predominantly focuses on adult cardiovascular health, leaving a gap in understanding their role in neonates.
Purpose of the Study:
- To review the metabolism of LCPUFAs and the function of SPMs.
- To explore the potential impact of SPMs on cardiovascular health and diseases specifically in the neonatal population.
- To highlight the need for further research into SPMs for neonatal cardiovascular health.
Main Methods:
- Literature review focusing on LCPUFAs metabolism and SPM functions.
- Analysis of existing studies on SPMs in cardiovascular health, with a specific emphasis on neonatal research.
- Synthesis of information regarding the anti-inflammatory and tissue-repairing properties of SPMs.
Main Results:
- SPMs are derived from LCPUFAs and possess both pro-resolving and anti-inflammatory properties.
- The efficacy of SPMs is influenced by the availability of LCPUFA precursors and cellular metabolic status.
- A significant knowledge gap exists regarding the specific roles and therapeutic potential of SPMs in neonatal cardiovascular conditions.
Conclusions:
- Understanding SPMs' role in neonatal cardiovascular health is critical.
- SPMs offer potential as novel therapeutic targets for cardiovascular dysfunction in neonates.
- Further investigation into LCPUFA metabolism and SPM pathways in neonates is warranted.
Abstract:
Cardiovascular disease remains a leading cause of mortality worldwide. Unresolved inflammation plays a critical role in cardiovascular diseases development. Specialized Pro-Resolving Mediators (SPMs), derived from long chain polyunsaturated fatty acids (LCPUFAs), enhances the host defense, by resolving the inflammation and tissue repair. In addition, SPMs also have anti-inflammatory properties. These physiological effects depend on the availability of LCPUFAs precursors and cellular metabolic balance. Most of the studies have focused on the impact of SPMs in adult cardiovascular health and diseases. In this review, we discuss LCPUFAs metabolism, SPMs, and their potential effect on cardiovascular health and diseases primarily focusing in neonates. A better understanding of the role of these SPMs in cardiovascular health and diseases in neonates could lead to the development of novel therapeutic approaches in cardiovascular dysfunction.
